Oncology Research Editorial Office

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090481 - 13 August 2026

Abstract This article has no abstract. More >

Yida Wang^1,#, Haiyue You^2,#, Jingyi Gao^3,#, Feng Zhang¹, Xin Ning², Xinfeng Yang², Zhiwen Qian¹, Ying Jiang², Lu Liu², Danping Wu², Yanfang Gu^1,2,*, Daozhen Chen^1,2,*, Yan Zhang^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085967 - 13 August 2026

Abstract Triple-negative breast cancer (TNBC) is characterized by marked metabolic plasticity, spatial heterogeneity, and therapy-induced adaptive remodeling. However, TNBC metabolism is often discussed as isolated pathways, making it difficult to link metabolic rewiring to immune exclusion, drug-tolerant persister cells, and treatment windows. Here, we propose a functional metabolic operating-state framework to organize recurrent adaptive programs in TNBC. Importantly, the S1–S5 framework is not a clinically validated subtype classification, but a set of coexisting and reversible operating states shaped by microenvironmental and therapeutic pressures. S1 represents a glycolysis–lactate/acidosis barrier; S2 denotes fatty acid oxidation (FAO)/oxidative phosphorylation (OXPHOS)-supported… More > Graphic Abstract

Iseult M. Browne^1,2, Susanna Slater¹, Myrto Kastrisiou¹, Mae Alghawas¹, Edward Phillips¹, Mark Beresford³, Stephen R. D. Johnston¹, Zoe Kemp¹, Emma Kipps¹, Marina Parton¹, Nicholas C. Turner^1,2, Alicia F. C. Okines^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085356 - 13 August 2026

Abstract Background: Adenoid cystic carcinoma (ACC) of the breast is a rare triple-negative malignancy with an indolent clinical course distinct from conventional triple-negative breast cancer (TNBC). Optimal management remains undefined due to limited prospective data. This study aimed to characterise the clinicopathological features, treatment patterns, and long-term outcomes of breast ACC at a high-volume specialist centre, contributing real-world evidence to inform management in the absence of prospective trial data. Methods: A single-institution retrospective cohort study was conducted of 24 patients with histopathologically confirmed breast ACC treated at The Royal Marsden NHS Foundation Trust between 2000 and… More >

Shih-Wei Chiang^1,2, Ming-Cheng Chen^2,3, Chang-Lin Lin², Yi-Lin Huang², Feng-Fan Chiang^2,4,*, Shun-Fa Yang^1,5,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085229 - 13 August 2026

Abstract Background: Anti-EGFR therapy is widely used as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC), particularly in patients with left-sided tumors. In liver-limited disease, maximizing tumor shrinkage may facilitate conversion to resectability; however, comparative real-world evidence among panitumumab, cetuximab, and bevacizumab remains limited. This study aimed to compare the clinical outcomes of these biologic agents in patients with RAS wild-type mCRC. Methods: We retrospectively analyzed 241 patients with RAS wild-type mCRC treated with first-line chemotherapy plus panitumumab (n = 76), cetuximab (n = 80), or bevacizumab (n = 85) between 2016 and 2024. Outcomes included depth of response… More >

Danning Zhao, Qin Liu^*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084736 - 13 August 2026

Abstract Cervical cancer, particularly its advanced stages, requires novel therapeutic paradigms. Cellular immunotherapy exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens. This review systematically evaluates four principal platforms under investigation: tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells. We critically analyze the preclinical rationale, clinical trial landscape, safety considerations, and manufacturing challenges for each modality. TIL therapy has achieved durable complete responses and an FDA Breakthrough Therapy designation. TCR-T cells enable precise targeting of intracellular viral epitopes but are HLA-restricted. CAR-T cells offer potent, MHC-independent recognition, yet face on-target/off-tumor More >

Chenchen Wang^1,2, Mingzhu Huang^1,2, Wenhua Li^1,2, Xuedan Sheng^1,2, Xiaoying Zhao^1,2, Xiaodong Zhu^1,2, Zhiyu Chen^1,2, Zhe Zhang^1,2, Haiming Li^2,3, Weijian Guo^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084378 - 13 August 2026

Abstract Background: Patients with refractory metastatic colorectal cancer (mCRC) face limited treatment options after failure of standard therapies. This single-arm, phase II study aimed to evaluate the efficacy and safety of rechallenge strategies using previously effective regimens in late-line mCRC. Methods: Patients who progressed after ≥2 lines of prior chemotherapy, with a prior progression-free survival (PFS) ≥4 months and a ≥4-month treatment-free interval on that regimen were enrolled. Patients received rechallenge chemotherapy (oxaliplatin-, irinotecan-, or raltitrexed-based) with or without targeted agents (bevacizumab or cetuximab). Primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate (ORR), disease… More >

Xueping Zhu^1,2,3,#, Misi He^1,2,3,#, Ling Wang^1,2,3,#, Rui Su⁴, Lin Zhong^1,2,3, Ting Guo^1,2,3,4, Haixia Wang^1,2,3,*, Dongling Zou^1,2,3,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083902 - 13 August 2026

Abstract Nucleocytoplasmic transport (NCT) regulates the spatial distribution of proteins and RNA between the nucleus and cytoplasm. NCT dysregulation can mislocalize tumor suppressors, DNA-repair factors, transcription factors, and drug targets in cancer. In this review, we conceptualize NCT-dependent protein mislocalization as a spatial regulatory framework for anticancer drug resistance, rather than as a catalogue of transport components. We systematically discuss how nuclear pore complex (NPC) remodeling, transport-receptor imbalance, post-translational modification (PTM)-regulated cargo routing, signaling-NCT crosstalk, nuclear localization signal/nuclear export signal (NLS/NES) alterations, and tumor microenvironmental pressures jointly drive aberrant nucleocytoplasmic distribution. These processes can further regulate… More >

Ling Li^1,2,#, Shuai Zhao^3,#, Xiaoxiao Wang², Jiahui Du², Zhen Jin¹, Song-Bai Liu^1,2,*, Xiaohua Li^2,3,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083636 - 13 August 2026

Abstract Breast cancer ranks first in global cancer incidence. Due to its high heterogeneity, cancer cells often develop drug resistance during metastasis, leading to therapeutic challenges and poor prognosis. Consequently, breast cancer organoid models have emerged, which can effectively recapitulate the tumor microenvironment and serve as important tools for investigating the mechanisms underlying breast cancer initiation and progression. Breast cancer organoids exhibit interactions between cells and the extracellular matrix (ECM) while retaining the heterogeneity of the original tumor cells. Owing to these advantages, such models have been widely applied in studies of tumor pathogenesis, disease modeling,… More >

Kyungeun Kim^1,2,#, Eunho Cho^3,#, Eun Joo Chung⁴, Kwon-Ho Song⁵, Tae Woo Kim^3,6, Seoung Wan Chae^1,*, Joon-Yong Chung^7,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083437 - 13 August 2026

Abstract Objectives: Gastric cancer remains a major global health burden, and robust biomarkers are needed to improve risk stratification. Although peptidyl-prolyl isomerase B (PPIB) has been suggested as a potential oncogenic factor, its clinical utility in gastric cancer remains unclear. This study aims to evaluate the clinicopathological and prognostic significance of PPIB mRNA expression and delineate its functional role in driving tumor progression. Methods: PPIB mRNA expression was evaluated in a retrospective cohort of 497 gastric cancer patients using RNAscope in situ hybridization and digital image analysis. Functional roles and underlying mechanism were assessed through siRNA-mediated knockdown, plasmid-driven overexpression,… More >

Jie Wu^1,2, Zhewei Zhang^1,2, Kit Ying Chan^1,2, Tat San Lau^1,2,*, Chi Chiu Wang^1,2,3,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083359 - 13 August 2026

Abstract Ovarian cancer is the most lethal gynecological malignancy, with most patients diagnosed at an advanced stage and eventually relapsed after post-platinum-taxane chemotherapy. High intratumoral heterogeneity, extensive peritoneal dissemination, and acquired chemoresistance continue to restrict the clinical benefits of current therapeutic strategies. Increasing evidence indicates that ovarian cancer stem cells (OCSCs), a rare but highly plastic subpopulation characterized by self-renewal, multilineage differentiation, quiescence, tumor-initiating capacity, and intrinsic stress tolerance, play pivotal roles in tumor initiation, metastasis, recurrence, and therapeutic resistance. In this review, we systematically summarize current knowledge regarding the identification and functional characterization of OCSCs More >